IL-2/CD80 Fusion Protein Dimer for Radiosensitization With Lower Toxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current radiation therapy for cancer is limited by radiation resistance of cancer cells and side effects from conventional sensitizers, necessitating a radiation enhancer that minimizes side effects while enhancing sensitivity.
Innovation Solution
A pharmaceutical composition comprising a fusion protein dimer of IL-2 protein and CD80 protein is used in combination with radiation therapy to enhance therapeutic efficacy and stimulate systemic immune cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional anticancer agents are used to enhance radiation therapy, then radiation sensitivity of cancer cells is improved, but toxicity and side effects increase
Solution Approach 1:
The invention divides the radiation therapy enhancement function into two separate components: (1) a radioprotector that protects normal tissues from radiation damage, and (2) a radiosensitizer that enhances cancer cell sensitivity to radiation. This segmentation allows each component to perform its specific function without the combined toxicity of conventional chemotherapeutic agents, resolving the contradiction between improving radiation sensitivity and reducing side effects
Solution Approach 2:
The invention introduces radioprotectors and radiosensitizers as intermediary substances that mediate the interaction between radiation and biological tissues. These intermediaries selectively modulate radiation effects - the radioprotector mitigates harmful effects on normal tissues while the radiosensitizer amplifies radiation damage in cancer cells, thereby enhancing therapeutic efficacy without proportionally increasing systemic toxicity
2Reliability
If high-dose radiation therapy is administered to overcome radiation resistance, then cancer treatment efficacy is improved, but damage to normal tissues increases
Solution Approach 1:
The invention applies different qualities to different locations: radioprotectors are administered to protect normal tissues (non-target areas) from radiation damage, while radiosensitizers are delivered to cancer cells (target areas) to enhance radiation sensitivity. This local differentiation of protective and sensitizing functions allows high-dose radiation to be administered safely, improving cancer treatment efficacy without proportionally increasing damage to normal tissues
Solution Approach 2:
The invention applies preliminary protective action by administering radioprotectors before radiation therapy to pre-shield normal tissues from radiation damage. This preliminary anti-action creates a protective barrier in advance, enabling subsequent high-dose radiation administration to cancer cells without causing excessive damage to surrounding healthy tissues, thereby resolving the contradiction between treatment efficacy and normal tissue protection
Data Source
AI summary
A pharmaceutical composition for enhancing radiation therapy, containing a fusion protein dimer is disclosed. The fusion protein dimer includes an IL-2 protein and a CD80 protein. A method of radiation therapy for cancer, using the composition is also disclosed. The composition for enhancing radiation therapy may increase the effect of radiation therapy in cancer treatment.